Pharma Mar, S.A.
MCE PHM.MC
Pharma Mar, S.A. Return on Equity (ROE) for the year ending December 31, 2023: 0.59%
-
Pharma Mar, S.A. Return on Equity (ROE) for the year ending December 31, 2022 was 22.14%, a -57.59% change year over year.
-
Pharma Mar, S.A. Return on Equity (ROE) for the year ending December 31, 2021 was 52.19%, a -60.94% change year over year.
-
Pharma Mar, S.A. Return on Equity (ROE) for the year ending December 31, 2020 was 133.62%, a 265.56% change year over year.
-
Pharma Mar, S.A. Return on Equity (ROE) for the year ending December 31, 2019 was -80.71%, a -211.66% change year over year.
| Date | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio |
|---|
| CEO | Mr. Jose Maria Fernandez Sousa-Faro Ph.D. |
| IPO Date | Sept. 8, 2000 |
| Location | Spain |
| Headquarters | Avenida de los Reyes, 1 |
| Employees | 509 |
| Sector | Health Care |
| Industries | |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Past 5 years
USD 3.77
USD 29.72
USD 7.78
USD 9.29
USD 7.02
StockViz Staff
January 15, 2025
Any question? Send us an email